1. Introduction {#sec1}
===============

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a huge burden on medical resources due to its high contagiousness, long incubation period, and the general susceptibility of the population ^\[^ [@bib1] ^\]^. However, the current treatment of COVID-19 is mainly palliative, and prompt and effective treatment planning at various stages of its course is challenging ^\[^ [@bib2] ^\]^.

In 2003, traditional Chinese medicine (TCM) showed satisfactory treatment outcomes in the early stages of the SARS epidemic ^\[^ [@bib3] ^\]^. Since the third edi- tion of \"Diagnosis and Treatment Protocol for COV- ID-19\" was released, TCM has been recommended for the treatment of COVID-19 ^\[^ [@bib4] ^\]^. The National Health Commission and the State Administration of Traditional Chinese Medicine jointly announced that TCM can reduces fever symptoms, glucocorticoid dosage, and complications and controls disease pro- gression. In various versions of the "Diagnosis and Treatment Protocol for COVID-19" and according to the theory of TCM, COVID-19 is caused by epidemic Qi and the disease is localized within the lungs. The basic pathogenesis is "wet, heat, poison and blood stasis". The basic prescriptions for dampness and stagnation of the lungs include Ephedra Herba (Ma Huang, 麻黄), Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁), Tsaoko Fructus (Cao Guo, 草果), For- sythiae Fructus (Lian Qiao, 连 翘 ), Atractylodis Rhizoma (Cang Zhu, 苍术) and Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草). The basic prescriptions for the syndrome of pathogenic toxin blockage of the lungs include Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁), Gypsum Fibrosum (Shi Gao, 石膏), Trichosanthis Fructus (Gua Lou, 瓜蒌), Rhei Radix Et Rhizoma (Da Huang, 大 黄 ), Ephedra Herba (Ma Huang, 麻 黄 ) and Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草). The basic prescriptions for the syndrome of pathogenic heat congesting the lung in- clude Ephedra Herba (Ma Huang, 麻 黄 ), Armeni- acae Semen Amarum (Ku Xing Ren, 苦 杏 仁 ), Gypsum Fibrosum (Shi Gao, 石膏), Fritillariae Thun- bergii Bulbus (Zhe Bei Mu, 浙贝母) and Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘 草 ). The basic pre- scriptions are mainly Ephedra Herba (Ma Huang, 麻 黄), Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁), Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草) and Gypsum Fibrosum (Shi Gao, 石膏) from Ma Xing Shi Gan Decoction (MXSGD). Meanwhile, the herbal formula Qing Fei Pai Du Decoction, which has good curative effects, is also mainly composed of MXSGD ^\[^ [@bib5] ^\]^.

This research group has conducted in-depth re- search on the antiviral and immunoregulatory mech- anisms of MXSGD. *In vitro* models have shown that MXSGD can directly inhibit influenza virus replica- tion; it has better virus adsorption inhibitory and host cell-protective effects than ribavirin [@bib6] ^,^ [@bib7]. MXSGD can also down-regulate IFN-*α*/*β* secretion and protein ex- pression of influenza virus-infected macrophages ^\[^ [@bib8] ^\]^. *In vivo* animal experiments showed that MXSGD can inhibit the activation of the TLR4-MyD88-TRAF6 sig- naling pathway and alleviate lung injury caused by influenza A virus in infected mice ^\[^ [@bib9] ^\]^. In summary, MXSGD has demonstrated satisfactory effects against influenza viruses. The use of bioinformatics coupled with the establishment of large network databases and the development of pharmacological computer simulation technologies facilitate significant pro- gress in pharmacology ^\[^ [@bib10] ^\]^. This is consistent with the overall system theory of TCM for treating diseases [@bib11] ^,^ [@bib12]. We used bioinformatics to explore the pharmacolo- gical mechanisms and effectiveness of MXSGD in the treatment of COVID-19-related pneumonia and provide theoretical guidance and support for clinical use.

2. Materials and Methods {#sec2}
========================

2.1. The bioactive compounds and targets of MXSGD {#sec2.1}
-------------------------------------------------

Using "Armeniacae Semen Amarum" "Glycyrrhizae Radix Et Rhizoma" "Ephedra Herba" "Gypsum Fibrosum" as keywords, the compounds of MXSGD were searched and collected from the TCM Database\@Taiwan (<http://tcm.cmu.edu.tw/zh-tw/> index.php) ^\[^ [@bib13] ^\]^ and Traditional Chinese Medicene Systems Parmacology Database and Analysis Platform(TCMSP)([http://tcmspw.com/index.php](http://tcmspw.com/index.php)){#intref0015})^\[^ [@bib14] ^\]^. Data on the pharmacokinetic parameters and these MXSGD targets were collected from TCMSP. Pharmacokinetic parameters included oral bioavailability (OB), Caco-2 permeability, and drug- likeness (DL). OB and Caco-2 permeability indicate the degree of absorption of a compound into the blood after oral administration [@bib15] ^,^ [@bib16]. DL, which refers to the similarity of a compound to a known drug, indicates the likelihood that the compound will become a drug ^\[^ [@bib17] ^\]^. According to the standards provided by the TCMSP database, all compounds were filtered, using OB \> 30%, Caco-2 \> − 0.4, and DL \> 0.18 as standards, to obtain orally absorbable MXSGD compounds with pharmacological acti- vity ^\[^ [@bib14] ^\]^. Finally, a total of 110 MXSGD bioactive compounds with targets were obtained. The details of each compound are shown in [Table 1](#tbl1){ref-type="table"} . The name of the collected target protein was imported into UniProtKB ([http://www.uniprot.org/),](http://www.uniprot.org/)){#intref0020} and the species was limited to "Homo sapiens" to allow the corrections of the names of the proteins to their official symbols.Table 1Information of active compounds in MXSGD.Table 1SourceMOL IDCompound nameMolecular weightOB (%)Caco-2DLArmeniacae Semen Amarum (Ku Xing Ren, 苦杏仁)MOL010921Estrone270.453.561.010.32MOL00221111,14-Eicosadienoic Acid308.5639.991.220.2MOL005030Gondoic Acid310.5830.71.20.2MOL000953Cholesterol386.7337.871.430.68MOL004355Spinasterol412.7742.981.440.76MOL007207Machiline285.3779.640.780.24MOL012922L-Stepholidine327.4187.350.760.54MOL000449Stigmasterol412.7743.831.440.76MOL000492(+)-Catechin290.2954.83− 0.030.24MOL000359Sitosterol414.7936.911.320.75MOL000211Mairin456.7855.380.730.78MOL002311Glycyrol366.3990.780.710.67MOL004841Licochalcone B286.376.760.470.19MOL004908Glabridin324.453.250.970.47MOL005017Phaseol336.3678.770.760.58Ephedra Herba (Ma Huang, 麻黄)MOL000422Kaempferol286.2541.880.260.24MOL000098Quercetin302.2546.430.050.28MOL004328Naringenin272.2759.290.280.21MOL000449Stigmasterol412.7743.831.440.76MOL000492(+)-Catechin290.2954.83− 0.030.24MOL010788Leucopelargonidin290.2957.97− 0.120.24MOL002823Herbacetin302.2536.070.120.27MOL004798Delphinidin303.2640.63− 0.020.28MOL000006Luteolin286.2536.160.190.25MOL000358Beta-Sitosterol414.7936.911.320.75MOL001494Mandenol308.56421.460.19MOL00175524-Ethylcholest-4-En-3-One412.7736.081.460.76MOL001771Poriferast-5-En-3beta-Ol414.7936.911.450.75MOL002881Diosmetin300.2831.140.460.27MOL004576Taxifolin304.2757.84− 0.230.27MOL005043Campesterol400.7637.581.320.71MOL005190Eriodictyol288.2771.790.170.24MOL005573Genkwanin284.2837.130.630.24MOL005842Pectolinarigenin314.3141.170.70.3MOL011319Truflex OBP334.543.740.90.24Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草)MOL001484Inermine284.2875.180.890.54MOL001792Liquiritigenin256.2732.760.510.18MOL000239Jaranol314.3150.830.610.29MOL002565Medicarpin270.349.2210.34MOL000354Isorhamnetin316.2849.60.310.31MOL003656Lupiwighteone338.3851.640.680.37MOL0038967-Methoxy-2-Methyl Isoflavone266.3142.561.160.2MOL000392Formononetin268.2869.670.780.21MOL000417Calycosin284.2847.750.520.24MOL004805(2S)-2-\[4-hydroxy-3-(3- methylbut-2-enyl)phenyl\]-8,8- dimethyl-2,3-dihydropyrano\[2,3-f\]chromen- 4-one (157414-03-4)390.5131.7910.72MOL004806Euchrenone406.5630.291.090.57MOL004808Glyasperin B370.4365.220.470.44MOL004810Glyasperin F354.3875.840.430.54MOL004811Glyasperin C356.4545.560.710.4MOL004814Isotrifoliol298.2631.940.530.42MOL004815Kanzonol B322.3839.620.660.35MOL004820Kanzonols W336.3650.480.630.52MOL004824(2S)-6-(2,4-Dihydroxyphenyl)-2-(2-Hydroxypropan-2-Yl)-4-Methoxy-2,3-Dihydrofuro\[3,2-G\]Chromen-7-One384.4160.2500.63MOL004827Semilicoisoflavone B352.3648.780.450.55MOL004828Glepidotin A338.3844.720.790.35MOL004829Glepidotin B340.464.460.460.34MOL004833Phaseolinisoflavan324.432.011.010.45MOL004835Glypallichalcone284.3361.60.760.19MOL004838Kanzonol U308.3558.4410.38MOL004848Licochalcone G354.4349.250.640.32MOL004849Licoarylcoumarin368.4159.620.40.43MOL004855Licoricone382.4463.580.530.47MOL004856Gancaonin A352.4151.080.80.4MOL004857Gancaonin B368.4148.790.580.45MOL004863Gancaonin L354.3866.370.520.41MOL004864Gancaonin M352.4130.490.90.41MOL004866Gancaonin O354.3844.150.480.41MOL004879Glycyrin382.4452.610.590.47MOL004882Licocoumarone340.433.210.840.36MOL004883Licoisoflavone A354.3841.610.370.42MOL004884Licoisoflavone B352.3638.930.460.55MOL004885Licoisoflavanone354.3852.470.390.54MOL004891Shinpterocarpin322.3880.31.10.73MOL0048985-Prenylbutein340.446.270.410.31MOL004904Licopyranocoumarin384.4180.360.130.65MOL004907Glyzaglabrin298.2661.070.340.35MOL004910Glabranin324.452.90.970.31MOL004911Glabrene322.3846.270.990.44MOL004912Glabrone336.3652.510.590.5MOL004913Hedysarimcoumestan B298.2648.140.480.43MOL0049141,3-Dihydroxy-8,9-Dimethoxy-6-Benzofurano\[3,2-C\]Chromenone328.2962.90.40.53MOL004915Eurycarpin A338.3843.280.430.37MOL004935Sigmoidin B356.434.880.420.41MOL004941(2R)-7-hydroxy 2-(4- hydroxyphenyl)chroman-4-one (578-86-9)256.2771.120.410.18MOL004945Isobavachin324.436.570.720.32MOL004948Isoglycyrol366.3944.70.910.84MOL004949Isolicoflavonol354.3845.170.540.42MOL004957Isoformononetin268.2838.370.790.21MOL0049591-Methoxyphaseollidin354.4369.981.010.64MOL004961Quercetin Der.330.3146.450.390.33MOL0049663\'-Hydroxy-4\'-O-Methylglabridin354.4343.7110.57MOL000497Licochalcone A338.4340.790.820.29MOL0049743\'-Methoxyglabridin354.4346.160.940.57MOL0049784\'-Methoxyglabridin338.4336.211.120.52MOL004980Inflacoumarin A322.3839.710.730.33MOL004985Icos-5-Enoic Acid310.5830.71.220.2MOL004988Kanzonol F420.5432.471.180.89MOL0049896-Prenylated Eriodictyol356.439.220.40.41MOL0049907,2\',4\'-Trihydroxy-5-methoxy-3-arylcoumarin (ZINC105741014)300.2883.710.240.27MOL0049917-Acetoxy-2-Methylisoflavone294.3238.920.740.26MOL0049938-Prenylated Eriodictyol356.453.790.430.4MOL004996Gadelaidic Acid310.5830.71.20.2MOL000500Vestitol272.3274.660.860.21MOL005000Gancaonin G352.4160.440.780.39MOL005001Gancaonin H420.4950.10.60.78MOL005003Licoagrocarpin338.4358.811.230.58MOL005007Glyasperins M368.4172.670.490.59MOL005008Glycyrrhiza Flavonol A370.3841.28− 0.090.6MOL005012Licoagroisoflavone336.3657.280.710.49MOL005016Odoratin314.3149.950.420.3MOL005018Xambioona388.4954.851.090.87MOL005020Dehydroglyasperins C340.453.820.680.37MOL000359Sitosterol414.7936.911.320.75MOL000211Mairin456.7855.380.730.78MOL002311Glycyrol366.3990.780.710.67MOL004841Licochalcone B286.376.760.470.19MOL004908Glabridin324.453.250.970.47MOL005017Phaseol336.3678.770.760.58MOL000422Kaempferol286.2541.880.260.24MOL000098Quercetin302.2546.430.050.28MOL004328Naringenin272.2759.290.280.21

2.2. SARS-CoV-2 target and protein-protein interaction (PPI) data collection {#sec2.2}
----------------------------------------------------------------------------

The OMIM database ([http://omim.org/](http://omim.org/)){#intref0025}) and Genecards (<http://www.genecards.org>) were used to collect data on the targets of SARS-CoV-2 [@bib18] ^,^ [@bib19]. Meanwhile, this study would also use the String database to collect PPI data for the targets of MXSGD and SARS-CoV-2. When collecting data, the species were limited to "Homo sapiens" with a confidence level of \> 0.4 ^\[^ [@bib20] ^\]^.

2.3. Network construction and analysis methods {#sec2.3}
----------------------------------------------

The MXSGD target, SARS-CoV-2 potential target, and PPI data were imported into the network visualization software, Cytoscape 3.7.2, to build and analyze the networks ^\[^ [@bib21] ^\]^. In the network, a node represents the active compound, target or pathway, and nodes are connected by edges. The meaning of an edge varies with networks ^\[^ [@bib21] ^\]^ The degree represents the number of connections between nodes, and betweenness represents the number of shortest paths through nodes ^\[^ [@bib21] ^\]^. In a large PPI network, there are dense areas of some molecular complexes, which are defined as clusters. In the MXSGD-SARS-CoV-2-PPI network, clusters can be considered as functional modules. It is possible to treat diseases by interacting with these functional modules ^\[^ [@bib21] ^\]^. The plug-in MCODE of Cytoscape 3.7.2 can analyze the PPI network to find clusters.

2.4. Gene Ontology (GO) and pathway enrichment analysis {#sec2.4}
-------------------------------------------------------

GO and pathway enrichment analyses can demon- strate the importance of different biological proce- sses and signaling pathways in the PPI network ^\[^ [@bib22] ^\]^. In this study, the DAVID platform version 6.8 (<https://david-d.ncifcrf.gov>) was used to perform GO enrichment and pathway enrichment analyses, and the results were displayed with network and bubble diagrams ^\[^ [@bib22] ^\]^.

3. Results {#sec3}
==========

3.1. The MXSGD and SARS-CoV-2 potential targets {#sec3.1}
-----------------------------------------------

A total of 272 MXSGD targets were obtained from TCMSP; Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草) had 227 targets, Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁) had 71 targets, Ephedra Herba (Ma Huang, 麻黄) had 215 targets and Gypsum Fibrosum (Shi Gao, 石膏) had 0 targets. Meanwhile, a total of 21 targets related to SARS-CoV-2-infected cells were collected. There is some overlap between the MXSGD and the SARS-CoV-2 potential target sets ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Venn diagram of MXSGD and SARS-CoV-2. GC represents Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草); KXR represents Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁); MH represents Ephedra Herba (Ma Huang, 麻黄).Figure 1

The relationship between the compounds and potential targets of MXSGD is shown in [Figure 2](#fig2){ref-type="fig"} . This network is composed of 110 compound nodes, 251 target nodes, and 2 069 edges. In this network, some targets can be regulated by a lot of compounds: PT- GS2 (94 edges), ESR1 (79 edges), CALM1 (75 edges), CALM2 (75 edges), CALM3 (75 edges), AR (70 edges) and NOS2 (69 edges). Some targets are also regu- lated by fewer compounds; PYGM, RAF1, RASA1, RASSF1 and RUNX1T1 are each regulated by one compound. Meanwhile, several compounds can reg- ulate a lot of targets: Quercetin (145 edges), Kaemp- ferol (62 edges), Luteolin (55 edges), 7-Methoxy-2- methyl isoflavone (43 edges), Formononetin (38 edges) and Isorhamnetin (35 edges). Several com- pounds can also regulate fewer targets: each of Icos- 5-enoic acid, Gadelaidic acid and Mairin can only regulate one target.Figure 2Compound-target network of MXSGD. Pink hexagons represent MXSGD targets. Red, orange and yellow circles represent compounds of Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草), Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁) and Ephedra Herba (Ma Huang, 麻黄), re- spectively. Green circles represent common compounds of Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草) and Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁). Blue circles represent common compounds of Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草) and Ephedra Herba (Ma Huang, 麻黄). Purple circles represent common compounds of Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁) and Ephedra Herba (Ma Huang, 麻黄).Figure 2

3.2. Analysis of the MXSGD-SARS-CoV-2-PPI network {#sec3.2}
-------------------------------------------------

The MXSGD-SARS-CoV-2-PPI network consists of 272 nodes (241 MXSGD target nodes, 23 SARS-CoV-2 potential target nodes, and 8 MXSGD-2019nCoV target node) and 5 541 edges ([Figure 3](#fig3){ref-type="fig"} ). The targets are arranged in descending order of Degree. The top 10 targets of each target group are: (1) MXSGD targets: AKT1 (163 edges), IL-6 (147 edges), MAPK3 (144 edges), TP53 (142 edges), TNF (134 edges), VEGFA (127 edges), JUN (122 edges), EGFR (121 edges), MAPK1 (118 edges) and MAPK8 (118 edges); (2) SARS-CoV-2 targets: CREB1 (99 edges), CCL5 (74 edges), CREBBP (62 edges), IRF3 (44 edges), IFNB1 (40 edges), LCN2 (29 edges), ATF2 (28 edges), IFNA1 (25 edges), MX1 (20 edges), BAG3 (18 edges) and CASP6 (18 edges); (3) MXSGD-SARS-CoV-2 targets: CASP3 (123 edges), FOS (109 edges), IL10 (92 edges), CCL2 (92 edges), BCL2L1 (78 edges), IFNG (68 edges), CXCL10 (63 edges) and DPP4 (29 edges).Figure 3MXSGD-SARS-CoV-2-PPI network. Orange, red and yellow circles represent MXSGD, SARS-CoV-2 potential and MXSGD-SARS-CoV-2 targets, respectively.Figure 3

3.3. Biological processes of the MXSGD-SARS-CoV- 2-PPI network {#sec3.3}
--------------------------------------------------------------

The MXSGD-SARS-CoV-2-PPI network was analyzed using MCODE, and 12 clusters were found ([Table 2](#tbl2){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"} ). The targets in the clusters were input into DAVID to perform GO enrichment analysis, and several biological processes were discovered.Table 2Clusters of the MXSGD-SARS-CoV-2-PPI networkTable 2ClusterScoreNodesEdgesTargets148.49621 479MYC, IL1B, CXCL8, JUN, IL-4, TGFB1, SERPINE1, PTEN, MPO, RELA, PARP1, AKT1, TNF, CRP, MAPK8, SPP1, MMP1, STAT1, ICAM1, SELE, VCAM1, CXCL10, FOS, CASP3, CREB1, CCL2, IFNG, IL-10, BCL2L1, STAT3, CCND1, MAPK1, CCL5, EGFR, VEGFA, CDKN1A, CASP9, MMP2, MMP9, PTGS2, IL-6, HSP90AA1, TP53, CAT, MDM2, AR, PPARG, ERBB2, MAPK14, MCL1, IL-2, NOS2, CCNB1, CD40LG, NOS3, MAPK3, ADIPOQ, MMP3, PLAU, EGF, HMOX1, HIF1A210.7038198RB1, CDK4, CAV1, IFNB1, F3, GJA1, ESR1, SIRT1, HSPB1, NFKBIA, APP, CASP7, GSK3B, CDK2, BIRC5, IL1A, CHEK1, XIAP, CXCL2, CHEK2, KDR, MET, MAPK10, ESR2, RUNX2, SOD1, CDK1, CCNA2, PGR, IGF2, IRF1, IRF3, AHR, CREBBP, CASP8, RAF1, NFE2L2, HSPA5310.381783OPRD1, LDLR, CHRM2, OPRK1, PTGER3, DRD2, PLAT, THBD, F2, CXCL11, ADRA2C, OPRM1, ADRA2B, ADCY2, DRD3, ADRA2A, CHRM447.50930MAOA, HTR2A, HTR3A, ADRA1A, HTR2C, ADRB1, ADRA1B, ADRA1D, SLC6A356.75927NR1I3, GSTM1, CYP1A1, AKR1C3, UGT1A1, CYP1B1, HSD3B2, HSD3B1, AKR1C163.3345PRKCB, ATF2, PRKCA, TOP2A73.0033CTSD, NCOA1, NCOA283.0033DGAT2, ACACA, FASN93.0033CYP1A2, NR1I2, CES1103.0033SCN5A, KCNMA1, KCNH2113.0033GRIA2, GABRA1, GABRA3122.8067DRD5, MAOB, CHRM5, CHRM3, DRD1, CHRM1Figure 4Clusters of the MXSGD-SARS-CoV-2-PPI network. Orange, red and yellow circles represent MXSGD, SARS-CoV-2 and MXSGD-SARS-CoV-2 targets, respectively.Figure 4

Cluster 1 is related to inflammatory responses (in- flammatory cells, inflammatory cytokines, and their signaling pathways), immune responses (T cells, monocytes, B cells and other immune cells), im- mune factors (including IFN-*γ* and TNF-*α*), virus de- fense, humoral immunity, and mucosal innate im- mune response. Cluster 2 is associated with leuko- cyte migration. Cluster 5 is involved in steroid meta- bolism. Cluster 3, 4, 6, 7, 8, 9, 10, 11 did not return any antiviral biological processes. The biological pro- cesses are shown in [Figure 5](#fig5){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"} .Figure 5Bubble chart of biological processes *x* axis represents fold enrichment.Figure 5Table 3Biological processes of the MXSGD-SARS-CoV-2-PPI networkTable 3ClustersTermBiological processesP valueTargetsFold enrichmentCluster 1GO:0006954Inflammatory response2.66 × 10^−13^IL-6, TNF, CCL2, PTGS2, RELA, CRP, CXCL8, CCL5, IL-10, TGFB1, CXCL10, AKT1, FOS, CD40LG, IL1B, SELE, SPP112.15GO:0001666Response to hypoxia1.02 × 10^−12^CCL2, CREB1, MMP2, ADIPOQ, TGFB1, VCAM1, CASP3, HIF1A, HMOX1, VEGFA, NOS2, CAT, PLAU20.47GO:0071456Cellular response to hypoxia~6.04\ ×\ 10~^−11^CCNB1, AKT1, ICAM1, HIF1A, PTGS2, HMOX1, VEGFA, TP53, MDM2, PTEN28.21GO:0000165MAPK cascade2.27 × 10^−9^EGFR, MAPK1, TNF, CCL2, ERBB2, MAPK3, IL1B, CCL5, EGF, MYC, TGFB1, IL-2212.40GO:0071347Cellular response to interleukin-16.49 × 10^−9^ICAM1, IL-6, HIF1A, CCL2, RELA, CXCL8, CCL5, MYCYC30.52GO:0051092Positive regulation of NF-kappaB Transcription factor activity2.59 × 10^−8^ICAM1, AR, IL-6, TNF, CD40LG, RELA, IL1B, CAT, TGFB118.33GO:0042102Positive regulation of T cell proliferation7.68 × 10^−8^IL-4, VCAM1, IL-6, CD40LG, IFNG, IL1B, CCL531.60GO:0006935Chemotaxis2.83 × 10^−7^IL-4, MAPK1, CCL2, MAPK14, CXCL8, CCL5, PLAU, CXCL101017.76GO:0006955Immune response2.92 × 10^−7^IL-4, IL6, TNF, CCL2, CD40LG, IFNG, CXCL8, IL1B, CCL5, IL-10, CXCL10, IL-27.72GO:0034097Response to cytokine1.22 × 10^−6^IL-4, FOS, MCL1, JUN, BCL2L1, STAT131.25GO:0043065Positive regulation of apoptotic process1.26 × 10^−6^AKT1, IL-6, TNF, PTGS2, HMOX1, CREB1, TP53, MAPK8, BCL2L1, TGFB19.03GO:0048146Positive regulation of fibroblast proliferation1.48 × 10^−6^CCNB1, EGFR, CDKN1A, JUN,\
MYC, TGFB130.09GO:0007159Leukocyte cell-cell adhesion1.88 × 10^−6^VCAM1, ICAM1, CD40LG, CCL5,\
SELE54.17GO:0007179Transforming growth factor beta receptor signaling pathway2.07 × 10^−5^FOS, CCL2, JUN, CREB1, PARP1,\
TGFB117.66GO:0071677Positive regulation of mononuclear cell migration7.75 × 10^−5^IIL-4, TNF, TGFB11203.13GO:0030593Neutrophil chemotaxis9.6 × 10^−5^CCL2, IFNG, CXCL8, IL1B, CCL520.52GO:0034612Response to tumor necrosis factor9.91 × 10^−5^CASP3, PTGS2, ADIPOQ, SELE43.33GO:0016032Viral process1.01 × 10^−4VCAM1,\ MAPK1,\ CREB1,\ MAPK3,^ TP53, MDM2, MMP1, STAT37.25GO:0032757Positive regulation of interleukin-8 production1.12 × 10^−4^TNF, SERPINE1, IL1B, ADIPOQ41.67GO:0006979Response to oxidative stress6.83 × 10^−4AKT1,\ EGFR,\ PTGS2,\ HMOX1,^ MPO12.31GO:0006959Humoral immune response1.16 × 10^−3^IL-6, TNF, CCL2, IFNG19.01GO:0071346Cellular response to interferon-gamma1.16 × 10^−3^CCL2, NOS2, CCL5, MYC19.01GO:0060397JAK-STAT cascade involved in growth hormone signaling pathway1.32 × 10^−3^MAPK1, MAPK3, STAT354.17GO:0030183B cell differentiation1.77 × 10^−3^IL-4, VCAM1, CD40LG, IL-10016.41GO:0030225Macrophage differentiation1.91 × 10^−3^MMP9, VEGFA, PARP145.14GO:0060333Interferon-gamma-mediated signaling pathway2.19 × 10^−3^VCAM1, ICAM1, IFNG, STAT115.26GO:0046427Positive regulation of JAK-STAT cascade2.86 × 10^−3^IIL-6, CCL5, IL-10036.93GO:0051607Defense response to virus3.04 × 10^−3^IL-IL-6, RELA, IFNG, STAT1, CXCL1008.21GO:0030890Positive regulation of B cell proliferation8.82 × 10^−3^IL-4, CDKN1A, IL-220.83GO:0050900Leukocyte migration9.91 × 10^−3^ICAM1, MMP9, SELE, MMP18.88GO:0032729Positive regulation of interferon-gamma production1.21 × 10^−2^TNF, IL1B, IL-217.66GO:0050852T cell receptor signaling pathway1.66 × 10^−2^MAPK1, RELA, IFNG, PTEN7.32GO:0051023Regulation of immunoglobulin secretion1.80 × 10^−2^TNF, CD40LG108.34GO:0042092Type 2 immune response Negative regulation of cytokine1.80 × 10^−2^IL-4, IL-100108.34GO:0002740secretion involved in the immune response2.16 × 10^−2^TNF, IL-1090.28GO:0045591Positive regulation of regulatory T cell differentiation2.16 × 10^−2^TGFB1, IL-290.28GO:0050776Regulation of immune response2.69 × 10^−2^IL-4, VCAM1, ICAM1, CD40LGG6.09GO:0097011Cellular response to granulocytemacrophage colony-stimulating factor stimulus2.87 × 10^−2^AKT1, MAPK167.71GO:0051024Positive regulation of immunoglobulin secretion3.93 × 10^−2^IL-6, IL-249.24GO:0060334Regulation of interferon-gammamediated signaling pathway4.62 × 10^−2^IFNG, STAT141.67Cluster 2GO:0016032Viral process4.73 × 10^−4^CREBBP, NFKBIA, RB1, CCNA2, SIRT1, KDR8.87GO:0043124Negative regulation of I-kappaB kinase/NF-kappaB signaling3.50 × 10^−3^CASP8, ESR1, SIRT133.14GO:0032481Positive regulation of type I interferon production5.63 × 10^−3^CREBBP, IRF1, IRF325.99GO:0048146Positive regulation of fibroblast proliferation6.29 × 10^−3^ESR1, CDK4, CCNA224.55GO:0060337Type I interferon signaling pathway8.74 × 10^−3^IFNB1, IRF1, IRF320.71GO:0071456Cellular response to hypoxia1.89 × 10^−2^NFE2L2, CCNA2, SIRT113.81GO:0045651Positive regulation of macrophage differentiation2.83 × 10^−2^CASP8, RB167.98GO:0030225Macrophage differentiation3.89 × 10^−2^CASP8, SIRT149.10GO:0030101Natural killer cell activation4.32 × 10^−2^IFNB1, CASP844.19GO:0051607Defense response to virus5.11 × 10^−2^IFNB1, IRF1, IRF38.03GO:0001666Response to hypoxia5.50 × 10^−2^CAV1, CREBBP, RAF17.71GO:0032728Positive regulation of interferon-beta production5.79 × 10^−2^IRF1, IRF332.73GO:0035666TRIF-dependent toll-like receptor signaling pathway5.99 × 10^−2^CASP8, IRF331.56Cluster 5GO:0008202Steroid metabolic process8.68 × 10^−7^AKR1C3, CYP1B1, CYP1A1, UGT1A1173.56GO:0055114Oxidation-reduction process2.75 × 10^−6^AKR1C3, HSD3B2, HSD3B1, CYP1B1, CYP1A1, AKR1C118.91GO:0042572Retinol metabolic process1.42 × 10^−2^AKR1C3, CYP1B1124.39GO:0006694Steroid biosynthetic process1.51 × 10^−2^HSD3B2, HSD3B1116.61

3.4. Herb-Pathway-Target network analysis {#sec3.4}
-----------------------------------------

The targets of the MXSGD-SARS-CoV-2-PPI network were input into DAVID to perform pathway enrichment analysis, and 10 antiviral signaling pathways were returned ([Figure 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} ). Of the targets in this network, Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘草) could regulate 72, Ephedra Herba (Ma Huang, 麻 黄 ) could regulate 70, and Armeniacae Semen Amarum (Ku Xing Ren, 苦杏仁) could regulate 13. This indicates that Ephedra Herba (Ma Huang, 麻 黄 ) and Glycyrrhizae Radix Et Rhizoma (Gan Cao, 甘 草 ) may have the most important antiviral properties, while Armeniacae Semen Amarum (Ku Xing Ren, 苦 杏 仁 ) may be supportive. The fold enrichment and *P* value, among others, of all signaling pathways are shown in [Table 4](#tbl4){ref-type="table"} and [Figure 7](#fig7){ref-type="fig"}. The most important of those signaling pathways is the TNF, and [Figure 8](#fig8){ref-type="fig"} shows that MXSGD can regulate multiple targets in the TNF pathway.Figure 6Herb-Pathway-Target network. Pink, blue and purple circles represent MXSGD, SARS-CoV-2 and MXSGD-SARS-CoV-2 targets, respectively. Red diamonds represent signaling pathways. Green hexagons represent herbs.Figure 6Figure 7Bubble chart of signaling pathways. *x* axis represents fold enrichment.Figure 7Table 4Signaling pathways of the MXSGD-SARS-CoV-2-PPI networkTable 4TermSignaling pathways*P* valueGenesFold enrichmenthsa04668TNF signaling pathway1.80 × 10^−19^CCL2, TNF, PTGS2, MMP9, CXCL2, NFKBIA, MMP3, CCL5, CXCL10, ATF2, VCAM1, AKT1, FOS, CASP3, CASP7, CASP8, IL1B, CHUK, PIK3CG, ICAM1, IL-6, RELA, CREB1, MAPK10, MAPK1, JUN, MAPK14, MAPK3, MAPK8, IKBKB, SELE8.07hsa04620Toll-like receptor signaling pathway2.00 × 10^−14^TNF, CXCL8, NFKBIA, CXCL11, CCL5, CXCL10, AKT1, FOS, IFNA1, CASP8, IL1B, CHUK, SPP1, PIK3CG, IL-6, RELA, MAPK10, STAT1, MAPK1, IFNB1, MAPK14, JUN, MAPK3, MAPK8, IRF3, IKBKB6.83hsa04151PI3K-AKT signaling pathway5.23 × 10^−14^HSP90AB1, MCL1, COL3A1, BCL2L1, PTEN, ATF2, AKT1, IFNA1, CASP9, BCL2, NOS3, EGF, INSR, MYC, CHUK, SPP1, PRKCA, IL-4, PIK3CG, EGFR, IL-6, HSP90AA1, CREB1, RELA, RXRA, MET, TP53, RAF1, BAD, CDK4, CDK2, KDR, MAPK1, CCND1, CDKN1A, IFNB1, CHRM2, GSK3B, CHRM1, MAPK3, VEGFA, MDM2, COL1A1, IKBKB, IL-23.63hsa04621NOD-like receptor signaling pathway3.11 × 10^−13^HSP90AB1, IL-6, TNF, CCL2, HSP90AA1, RELA, CXCL2, CXCL8, NFKBIA, MAPK10, CCL5, MAPK1, MAPK14, CASP8, MAPK3, IL1B, MAPK8, IKBKB, CHUK9.45hsa04068FoxO signaling pathway8.05 × 10^−13^PTEN, IL-10, TGFB1, AKT1, SLC2A4, CAT, EGF, INSR, CHUK, EGFR, PIK3CG, IL-6, CREBBP, RAF1, MAPK10, SIRT1, CDK2, STAT3, CCNB1, MAPK1, CDKN1A, CCND1, MAPK14, MAPK3, MDM2, MAPK8, IKBKB5.61hsa04660T cell receptor signaling pathway2.26 × 10^−10^IL-4, PIK3CG, TNF, RELA, RAF1, NFKBIA, CDK4, IL-10, AKT1, FOS, MAPK1, CD40LG, JUN, GSK3B, MAPK14, IFNG, MAPK3, PPP3CA, IKBKB, CHUK, IL-25.85hsa04064NF-kappa B signaling pathway2.03 × 10^−6^ICAM1, TNF, XIAP, PTGS2, RELA, NFKBIA, CXCL8, BCL2L1, VCAM1, CD40LG, BCL2, IL1B, IKBKB, CHUK, PLAU4.80hsa04662B cell receptor signaling pathway4.81 × 10^−6^PIK3CG, AKT1, FOS, MAPK1, JUN, GSK3B, RELA, MAPK3, RAF1, NFKBIA, PPP3CA, IKBKB, CHUK5.25hsa04630Jak-STAT signaling pathway1.95 × 10^−4^IL-4, PIK3CG, IL-6, CREBBP, PIM1, BCL2L1, STAT1, IL-10, STAT3, AKT1, IFNA1, CCND1, IFNB1, IFNG, MYC, IL-23.07hsa04666Fc gamma R-mediated phagocytosis3.01 × 10^−2^PRKCA, PIK3CG, AKT1, MAPK1, NCF1, MAPK3, RAF1, PRKCB2.65Figure 8TNF pathway modified from hsa04668. Orange, pink and yellow represent MXSGD, SARS-CoV-2 and MXSGD-SARS-CoV-2 targets, respectively.Figure 8

4. Discussion {#sec4}
=============

This study used bioinformatics to construct and analyze the MXSGD compound-target, MXSGD- SARS-CoV-2-PPI and Herb-Pathway-Target networks. It revealed the multi-path and multi- molecular target mechanisms of MXSGD against COVID-19, which provides a basis for clinical use. In TCM, clinical diagnosis and treatment are based on syndrome differentiation. TCM associates the attributes of herbs with human meridians and collaterals and demonstrates the selectivity of herbs for the viscera to guide clinical practice ^\[^ [@bib23] ^\]^. Under the theoretical framework of TCM, COVID-19 belongs to the fiels of the plague of dampness pathogen. The etiology attribute is "pathogen of damp toxin". The disease is localized in the lung and spleen, and the basic pathogenesis is characterized as "wet, poison, stasis and closure" ^\[^ [@bib24] ^\]^. The results of pathological anatomy also confirmed that the damage caused by the new coronavirus is mainly in the lungs ^\[^ [@bib25] ^\]^.

By analyzing the MXSGD-SARS-CoV-2-PPI net- work, we found that some targets of MXSGD can in- teract with ACE (including ESR1, PTGS2, CAT, PPARG, NOS2, F2, NOS3, KDR, ADRA1B, ADRB2, ADRA1D, NR3C2, ACHE, SLC6A4, ADRB1, HMOX1, ADRA1A, PON1 and NPEPPS). Other targets can in- teract with ACE2 (CAT, NOS3, NR3C2, ACHE, LTA4H, NCF1, CDK4, IL-6, MAPK3, HIF1A, CRP, NPEPPS, CALM1, CALM2 and CALM3). Those indicate that MXSGD may regulate the expression of ACE2 receptors in various organs affected by COVID-19.

SARS-CoV-2 can induce inflammatory storms. When it infects the human body, it can invade cells through ACE2 ^\[^ [@bib26] ^\]^. The lung tissues that highly ex- press ACE2 and are externally exposed become the main targets. Immune cells in the lung are over-activ- ated, and they produce several inflammatory factors, such as interferon (IFN), interleukin (IL), chemokines, colony-stimulating factors (CSFs), tu- mor necrosis factor (TNF) ^\[^ [@bib27] ^\]^. These cytokines are secreted by certain immune cells, and they may pro- mote or inhibit inflammation. They maintain a bal- anced state within the normal human body ^\[^ [@bib28] ^\]^. Pro- inflammatory factors can activate and recruit other immune cells. Immune cells can secrete more cy- tokines and activate and recruit more immune cells, thus forming a positive feedback loop that leads to an inflammation storm. Eventually, several immune cells and the interstitial fluid accumulate in the lungs, which block the gas exchange between alveoli and capillaries, resulting in acute respiratory distress syn- drome and death in many patients ^\[^ [@bib29] ^\]^. The current study found that MXSGD can regulate inflammatory responses (GO:0006954, GO:0050727, GO:0002674), immune factors and their mediated pathways (in- cluding IFN-*γ*, TNF-*α*, IL-1 and IL-6) (GO:0071347), and the activation, proliferation and chemotaxis of immune cells (macrophages, T cells, B cells, white blood cells and so on) (such as GO:0050852, GO:0042110, GO:0010818, GO:0030225, GO:0006955). Our previous research also showed that MXSGD can effectively reduce lung inflammation, protect im- mune organs and regulate cytokine balance, which constitute the possible mechanisms for alleviating lung injury in mice caused by the inhibition of the TLR4-MyD88-TRAF6 signaling pathway by influenza

A viruses ^\[^ [@bib9] ^\]^. Recent studies have shown that patients with COVID-19 often have concomitant influenza and parainfluenza virus infections, especially in severe cases; hence, treatment for multiple infec- tions is required. Our previous research provided valuable insights into the antiviral and antibacterial properties of MXSGD; it revealed that MXSGD can in- hibit the replication of the influenza virus by regulat- ing the body\'s immunity ^\[^ [@bib30] ^\]^. In addition, the results of pathway enrichment analysis showed that MXSGD can inhibit immune factors and prevent excessive immune response by regulating the TNF, NOD-like receptor, FoxO, PI3K-AKT, Toll-like receptor, T cell receptor, NF-kappa B, B cell receptor and Jak-STAT signaling pathways, as well as Fc gamma R-mediated phagocytosis.

According to the current \"Diagnosis and Treat- ment Protocol for COVID-19\" (Trial Version 5 - 7) is- sued by the National Health Commission, MXSGD is recommended for the treatment of severe cases (es- pecially for the patients with the syndrome of epi- demic virus attacking lung) ^\[^ [@bib31] ^\]^. Recent studies have shown that severe cases have a higher proportion of cytokine storms, leading to worse prognoses ^\[^ [@bib32] ^\]^. Ex- amination of blood cytokines in severe cases re- vealed that the D-dimer increase, while peripheral blood lymphocytes progressively decrease; their cy- tokines IL-2, IL-7, IL-10, GCSF, IP10, MCP1, MIP1A and TNF-*α* are also higher than normal ^\[^ [@bib33] ^\]^. Such high levels of pro-inflammatory cytokines may cause shock and damage to the heart, liver and kidneys, as well as respiratory or multiple organ failure. The aforementioned cytokines also extensively mediate lung pathological changes, which may result in ex- tensive infiltration of neutrophils and macrophages, and subsequent diffuse alveolar injury [@bib34] ^,^ [@bib35].

WEI et al. ^\[^ [@bib36] ^\]^ conducted a comprehensive immuno- logical analysis of the blood samples of 33 COVID-19 patients and found the key mechanism for the in- flammatory storm. After SARS-CoV-2 infection, pathogenic T cells are rapidly activated, producing cytokines such as GM-CSF and IL-6. GM-CSF further activates CD14 + and CD16 + inflammatory mono- cytes, thereby producing a large amount of IL-6 and other inflammatory factors. This facilitates the forma- tion of an inflammatory storm and results in severe lung and immune system damage ^\[^ [@bib37] ^\]^. Therefore, IL-6 and GM-CSF are the two key inflammatory factors that trigger the inflammatory storm in patients with COVID-19 ^\[^ [@bib38] ^\]^

In summary, the main mechanism of MXSGD in the treatment of patients with severe COVID-19 pneumonia is the regulation of biological modules, such as the inflammatory and immune biological modules. Our previous studies demonstrated the in-hibition of inflammatory storms in the H1N1 influ- enza mouse model by MXSGD. A recent research also showed that Lian Hua Qing Wen Capsule, composed of MXSGD and Yin Qiao Powder, can significantly in- hibit the replication of SARS-CoV-2 in Vero E6 cells at the mRNA level and the production of pro-inflam- matory cytokines (TNF-*α*, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) ^\[^ [@bib39] ^\]^. In addition, Lian Hua Qing Wen Capsule treatment can cause abnormal morphologic- al changes within virus particles in the cells ^\[^ [@bib39] ^\]^.

More importantly, our previous research on influ- enza A virus found that, the MXSGD clinical equival- ent dose, and twice of it, can reduce the levels of TNF-*α* and IL-4, significantly increase the thymus and spleen indexes, and improve the pathological damage of the lung tissues ^\[^ [@bib40] ^\]^. In the comprehensive management of COVID-19, MXSGD and its modified formulae are mainly used in critically ill patients. A cascade of inflammatory events occur in patients, and leveraging multiple mechanisms to counteract their effects is crucial to patient recovery and surviv- al. This systematic pharmacological study and previ- ous studies have revealed the underlying mechan- isms of MXSGD in the regulation of the biological module of inflammation. Therefore, this study provides important evidence for the clinical use of MXSGD in the treatment of severely ill patients with COVID-19.

5. Conclusions {#sec5}
==============

MXSGD can control disease progression by regulating multiple compounds and targets; it can reduce inflammation and balance immunity by regulating several proteins interacting with ACE2 and a series of signaling pathways closely related to disease development. This study provides evidence to facilitate further research into MXSGD and its clinical adoption for the treatment of COVID-19.
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